| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| AIDS Vaccines | 40 | 2024 | 898 | 5.540 |
Why?
|
| Immunization, Secondary | 27 | 2025 | 373 | 4.070 |
Why?
|
| Immunocompromised Host | 31 | 2024 | 866 | 3.020 |
Why?
|
| Antibodies, Viral | 61 | 2025 | 3211 | 2.870 |
Why?
|
| Mycoses | 23 | 2020 | 389 | 2.800 |
Why?
|
| Disease Transmission, Infectious | 37 | 2022 | 560 | 2.800 |
Why?
|
| Coronavirus Infections | 45 | 2020 | 3100 | 2.420 |
Why?
|
| HIV Antibodies | 28 | 2024 | 1337 | 2.260 |
Why?
|
| Pneumonia, Viral | 44 | 2020 | 3223 | 2.200 |
Why?
|
| HIV-1 | 36 | 2024 | 6944 | 2.190 |
Why?
|
| Antibodies, Neutralizing | 45 | 2025 | 2010 | 2.180 |
Why?
|
| Antiviral Agents | 33 | 2024 | 3050 | 2.150 |
Why?
|
| Opportunistic Infections | 13 | 2024 | 376 | 2.050 |
Why?
|
| Antifungal Agents | 25 | 2016 | 769 | 1.920 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 33 | 2023 | 5753 | 1.890 |
Why?
|
| Viral Vaccines | 24 | 2024 | 597 | 1.840 |
Why?
|
| Vaccination | 44 | 2024 | 3426 | 1.750 |
Why?
|
| Vaccines | 12 | 2023 | 841 | 1.600 |
Why?
|
| Communicable Disease Control | 21 | 2022 | 856 | 1.590 |
Why?
|
| Pandemics | 59 | 2024 | 8703 | 1.570 |
Why?
|
| Lung Transplantation | 10 | 2019 | 1311 | 1.570 |
Why?
|
| Aspergillosis | 16 | 2020 | 242 | 1.550 |
Why?
|
| Adenoviruses, Human | 4 | 2014 | 258 | 1.510 |
Why?
|
| Antibodies, Monoclonal | 31 | 2023 | 9249 | 1.470 |
Why?
|
| Hemorrhagic Fever, Ebola | 5 | 2022 | 424 | 1.440 |
Why?
|
| Hepatitis C | 7 | 2022 | 1597 | 1.300 |
Why?
|
| Virus Diseases | 6 | 2023 | 718 | 1.280 |
Why?
|
| Masks | 5 | 2023 | 209 | 1.220 |
Why?
|
| Anti-Infective Agents | 9 | 2020 | 986 | 1.210 |
Why?
|
| Vaccines, Synthetic | 18 | 2024 | 621 | 1.210 |
Why?
|
| Humans | 455 | 2025 | 765968 | 1.200 |
Why?
|
| Vaccines, DNA | 12 | 2023 | 279 | 1.160 |
Why?
|
| HIV Infections | 35 | 2024 | 17533 | 1.150 |
Why?
|
| Pneumonia, Pneumocystis | 6 | 2018 | 239 | 1.130 |
Why?
|
| Vaccinia virus | 11 | 2023 | 327 | 1.130 |
Why?
|
| Adjuvants, Immunologic | 9 | 2024 | 995 | 1.110 |
Why?
|
| Antibiotic Prophylaxis | 8 | 2023 | 644 | 1.090 |
Why?
|
| Immunization Programs | 8 | 2022 | 267 | 1.080 |
Why?
|
| Rheumatic Diseases | 9 | 2023 | 622 | 1.050 |
Why?
|
| Vaccinia | 2 | 2019 | 71 | 1.050 |
Why?
|
| Lymphopenia | 4 | 2023 | 297 | 1.050 |
Why?
|
| Leukemia | 9 | 2022 | 1522 | 1.030 |
Why?
|
| Public Health Practice | 11 | 2022 | 219 | 1.010 |
Why?
|
| Disease Outbreaks | 8 | 2024 | 1759 | 0.980 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 9 | 2024 | 381 | 0.960 |
Why?
|
| Meningococcal Vaccines | 2 | 2023 | 96 | 0.960 |
Why?
|
| Clinical Laboratory Techniques | 9 | 2020 | 747 | 0.930 |
Why?
|
| Viruses | 3 | 2022 | 371 | 0.920 |
Why?
|
| Cytomegalovirus Infections | 9 | 2023 | 836 | 0.900 |
Why?
|
| Musculoskeletal Diseases | 7 | 2023 | 598 | 0.900 |
Why?
|
| Triazoles | 8 | 2013 | 897 | 0.880 |
Why?
|
| Drug Approval | 8 | 2023 | 818 | 0.860 |
Why?
|
| Communicable Diseases | 6 | 2022 | 874 | 0.860 |
Why?
|
| Pneumocystis carinii | 5 | 2018 | 70 | 0.860 |
Why?
|
| Rheumatology | 9 | 2023 | 602 | 0.860 |
Why?
|
| Meningococcal Infections | 1 | 2023 | 78 | 0.840 |
Why?
|
| Hematologic Neoplasms | 8 | 2024 | 1927 | 0.830 |
Why?
|
| Respiratory Tract Infections | 4 | 2023 | 1008 | 0.820 |
Why?
|
| United States Food and Drug Administration | 10 | 2022 | 1672 | 0.820 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2021 | 226 | 0.810 |
Why?
|
| Neutropenia | 10 | 2012 | 893 | 0.790 |
Why?
|
| Influenza, Human | 7 | 2024 | 1539 | 0.780 |
Why?
|
| Ebolavirus | 2 | 2014 | 250 | 0.770 |
Why?
|
| beta-Glucans | 5 | 2012 | 129 | 0.770 |
Why?
|
| Adenosine Monophosphate | 7 | 2021 | 231 | 0.770 |
Why?
|
| Immunoglobulin G | 14 | 2024 | 4528 | 0.760 |
Why?
|
| Gene Products, env | 2 | 2012 | 251 | 0.760 |
Why?
|
| Epidemics | 3 | 2021 | 514 | 0.740 |
Why?
|
| Smallpox Vaccine | 5 | 2013 | 77 | 0.720 |
Why?
|
| Ritonavir | 4 | 2022 | 330 | 0.710 |
Why?
|
| Immunity, Cellular | 12 | 2024 | 1555 | 0.710 |
Why?
|
| Quarantine | 6 | 2021 | 185 | 0.710 |
Why?
|
| Alanine | 7 | 2021 | 612 | 0.710 |
Why?
|
| Vaccines, Attenuated | 7 | 2020 | 312 | 0.700 |
Why?
|
| Immunity, Humoral | 6 | 2024 | 605 | 0.700 |
Why?
|
| Double-Blind Method | 30 | 2024 | 12437 | 0.700 |
Why?
|
| Immunity, Mucosal | 4 | 2022 | 498 | 0.700 |
Why?
|
| Herpes Zoster | 3 | 2021 | 252 | 0.700 |
Why?
|
| Emergencies | 3 | 2023 | 1223 | 0.690 |
Why?
|
| Smallpox | 1 | 2019 | 43 | 0.660 |
Why?
|
| Hydroxychloroquine | 8 | 2021 | 431 | 0.650 |
Why?
|
| Gram-Positive Bacterial Infections | 4 | 2014 | 339 | 0.640 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2014 | 239 | 0.640 |
Why?
|
| Immunization, Passive | 11 | 2023 | 616 | 0.640 |
Why?
|
| Herpes Zoster Vaccine | 3 | 2021 | 50 | 0.630 |
Why?
|
| Adult | 129 | 2025 | 223044 | 0.630 |
Why?
|
| Genetic Vectors | 21 | 2023 | 3404 | 0.630 |
Why?
|
| Public Health | 7 | 2023 | 2680 | 0.620 |
Why?
|
| Vaccines, Combined | 6 | 2023 | 70 | 0.610 |
Why?
|
| Anti-Bacterial Agents | 15 | 2023 | 7478 | 0.600 |
Why?
|
| Acyclovir | 1 | 2019 | 267 | 0.600 |
Why?
|
| Herpesvirus 3, Human | 1 | 2019 | 159 | 0.590 |
Why?
|
| Immunologic Factors | 5 | 2021 | 1587 | 0.570 |
Why?
|
| Middle Aged | 113 | 2025 | 223009 | 0.560 |
Why?
|
| State Government | 3 | 2021 | 388 | 0.560 |
Why?
|
| Adenoviridae | 13 | 2021 | 1092 | 0.560 |
Why?
|
| Bacterial Infections | 5 | 2020 | 1387 | 0.540 |
Why?
|
| Mannans | 6 | 2014 | 57 | 0.540 |
Why?
|
| Young Adult | 59 | 2024 | 59889 | 0.530 |
Why?
|
| Urinary Tract Infections | 2 | 2022 | 805 | 0.530 |
Why?
|
| Clinical Trials as Topic | 21 | 2024 | 8041 | 0.530 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 13 | 2020 | 3807 | 0.520 |
Why?
|
| Graft vs Host Disease | 13 | 2023 | 3078 | 0.520 |
Why?
|
| Biomedical Research | 10 | 2023 | 3458 | 0.520 |
Why?
|
| Ofloxacin | 3 | 2006 | 66 | 0.510 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2010 | 452 | 0.510 |
Why?
|
| Lung Diseases, Fungal | 2 | 2014 | 123 | 0.510 |
Why?
|
| Editorial Policies | 4 | 2022 | 458 | 0.500 |
Why?
|
| Influenza Vaccines | 3 | 2024 | 778 | 0.500 |
Why?
|
| Male | 133 | 2025 | 363698 | 0.500 |
Why?
|
| Anti-Retroviral Agents | 3 | 2012 | 1787 | 0.500 |
Why?
|
| Female | 135 | 2025 | 396112 | 0.490 |
Why?
|
| Immunosuppressive Agents | 9 | 2020 | 4209 | 0.480 |
Why?
|
| Pyrimidines | 8 | 2021 | 3047 | 0.480 |
Why?
|
| Antirheumatic Agents | 5 | 2023 | 1365 | 0.470 |
Why?
|
| Job Description | 1 | 2014 | 61 | 0.470 |
Why?
|
| Aspergillus | 5 | 2014 | 93 | 0.460 |
Why?
|
| Neoplasms | 14 | 2024 | 22340 | 0.460 |
Why?
|
| Viral Load | 11 | 2024 | 3386 | 0.450 |
Why?
|
| Candidiasis | 4 | 2012 | 371 | 0.450 |
Why?
|
| Hepatitis B | 3 | 2014 | 707 | 0.450 |
Why?
|
| Influenza in Birds | 2 | 2024 | 76 | 0.440 |
Why?
|
| Molecular Diagnostic Techniques | 4 | 2013 | 618 | 0.430 |
Why?
|
| Birds | 2 | 2024 | 165 | 0.430 |
Why?
|
| Glucocorticoids | 7 | 2021 | 2132 | 0.430 |
Why?
|
| Rape | 1 | 2014 | 131 | 0.430 |
Why?
|
| Hepatitis C, Chronic | 2 | 2022 | 1032 | 0.430 |
Why?
|
| Bacteremia | 4 | 2018 | 989 | 0.430 |
Why?
|
| United States | 53 | 2024 | 72903 | 0.430 |
Why?
|
| Hepatitis B virus | 2 | 2014 | 530 | 0.420 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2014 | 113 | 0.420 |
Why?
|
| Malaria | 1 | 2023 | 1246 | 0.420 |
Why?
|
| Orthopoxvirus | 1 | 2012 | 10 | 0.420 |
Why?
|
| Information Dissemination | 5 | 2021 | 1142 | 0.410 |
Why?
|
| HIV Seronegativity | 2 | 2011 | 209 | 0.410 |
Why?
|
| Coccidioidomycosis | 2 | 2009 | 36 | 0.410 |
Why?
|
| Thoracostomy | 1 | 2013 | 78 | 0.410 |
Why?
|
| Cefazolin | 1 | 2013 | 94 | 0.400 |
Why?
|
| Drugs, Investigational | 1 | 2014 | 211 | 0.400 |
Why?
|
| Journalism, Medical | 3 | 2021 | 73 | 0.400 |
Why?
|
| Chest Tubes | 1 | 2013 | 153 | 0.400 |
Why?
|
| Fever | 7 | 2010 | 1603 | 0.400 |
Why?
|
| Fluconazole | 4 | 2015 | 154 | 0.400 |
Why?
|
| Organizational Policy | 1 | 2014 | 434 | 0.400 |
Why?
|
| Heart Transplantation | 4 | 2019 | 3310 | 0.400 |
Why?
|
| International Cooperation | 5 | 2021 | 1432 | 0.390 |
Why?
|
| Health Services Accessibility | 9 | 2022 | 5508 | 0.390 |
Why?
|
| Microcephaly | 1 | 2016 | 426 | 0.380 |
Why?
|
| Mass Media | 4 | 2021 | 301 | 0.380 |
Why?
|
| Amphotericin B | 4 | 2012 | 140 | 0.380 |
Why?
|
| Tissue Donors | 6 | 2022 | 2395 | 0.370 |
Why?
|
| Adolescent | 53 | 2024 | 88835 | 0.370 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2022 | 2674 | 0.370 |
Why?
|
| Vancomycin Resistance | 2 | 2002 | 125 | 0.370 |
Why?
|
| Aged | 67 | 2025 | 171117 | 0.370 |
Why?
|
| Transplantation | 2 | 2011 | 222 | 0.360 |
Why?
|
| Transplantation, Homologous | 13 | 2014 | 4860 | 0.360 |
Why?
|
| Injections, Intramuscular | 5 | 2024 | 552 | 0.360 |
Why?
|
| Interleukin-12 | 3 | 2024 | 579 | 0.360 |
Why?
|
| Capsid Proteins | 1 | 2014 | 467 | 0.360 |
Why?
|
| Central Nervous System Fungal Infections | 2 | 2008 | 23 | 0.350 |
Why?
|
| Serum | 5 | 2014 | 206 | 0.350 |
Why?
|
| Lymphadenitis | 1 | 2011 | 98 | 0.350 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2021 | 1808 | 0.350 |
Why?
|
| Communication | 8 | 2022 | 3916 | 0.350 |
Why?
|
| Fetal Diseases | 1 | 2016 | 914 | 0.350 |
Why?
|
| Bacterial Vaccines | 1 | 2012 | 400 | 0.350 |
Why?
|
| Leukocytes, Mononuclear | 5 | 2024 | 1857 | 0.340 |
Why?
|
| Dexamethasone | 7 | 2021 | 1963 | 0.340 |
Why?
|
| Plateletpheresis | 2 | 2020 | 39 | 0.330 |
Why?
|
| Contact Tracing | 3 | 2020 | 274 | 0.330 |
Why?
|
| Polymerase Chain Reaction | 6 | 2013 | 6069 | 0.330 |
Why?
|
| Antineoplastic Agents | 11 | 2018 | 13648 | 0.330 |
Why?
|
| Surgical Wound Infection | 3 | 2013 | 1543 | 0.320 |
Why?
|
| Health Personnel | 7 | 2022 | 3390 | 0.320 |
Why?
|
| Severity of Illness Index | 9 | 2022 | 15880 | 0.320 |
Why?
|
| Placebos | 7 | 2021 | 1659 | 0.320 |
Why?
|
| Treatment Outcome | 37 | 2022 | 65188 | 0.310 |
Why?
|
| Tissue and Organ Procurement | 1 | 2017 | 989 | 0.310 |
Why?
|
| Vaccines, Conjugate | 3 | 2023 | 334 | 0.310 |
Why?
|
| HIV Antigens | 3 | 2019 | 328 | 0.310 |
Why?
|
| Organ Transplantation | 4 | 2025 | 1174 | 0.300 |
Why?
|
| Antibodies, Neoplasm | 2 | 2008 | 282 | 0.300 |
Why?
|
| Pneumonia | 3 | 2022 | 2157 | 0.300 |
Why?
|
| Candida albicans | 1 | 2011 | 377 | 0.300 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2014 | 667 | 0.300 |
Why?
|
| Skin Diseases, Infectious | 1 | 2008 | 73 | 0.300 |
Why?
|
| Biological Evolution | 2 | 2022 | 1072 | 0.300 |
Why?
|
| Time Factors | 29 | 2023 | 40065 | 0.300 |
Why?
|
| B-Lymphocytes | 5 | 2024 | 4778 | 0.290 |
Why?
|
| Drug Carriers | 4 | 2018 | 700 | 0.290 |
Why?
|
| Patient Care | 4 | 2022 | 629 | 0.290 |
Why?
|
| Adenine | 2 | 2018 | 994 | 0.290 |
Why?
|
| Specimen Handling | 3 | 2020 | 704 | 0.290 |
Why?
|
| Periodicals as Topic | 5 | 2022 | 1462 | 0.290 |
Why?
|
| Deoxycytidine | 1 | 2012 | 889 | 0.290 |
Why?
|
| Blood Donors | 2 | 2020 | 342 | 0.280 |
Why?
|
| Enterococcus | 2 | 2014 | 157 | 0.280 |
Why?
|
| Soft Tissue Infections | 2 | 2008 | 167 | 0.280 |
Why?
|
| Deoxycholic Acid | 1 | 2007 | 54 | 0.280 |
Why?
|
| Antibody Formation | 5 | 2021 | 1391 | 0.280 |
Why?
|
| Drug Administration Schedule | 10 | 2021 | 4850 | 0.280 |
Why?
|
| Systemic Inflammatory Response Syndrome | 3 | 2021 | 622 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2024 | 10383 | 0.270 |
Why?
|
| Dermatomycoses | 1 | 2007 | 45 | 0.270 |
Why?
|
| CD4-Positive T-Lymphocytes | 8 | 2024 | 4405 | 0.270 |
Why?
|
| Antigens, Viral | 7 | 2021 | 995 | 0.270 |
Why?
|
| Hepacivirus | 4 | 2022 | 1343 | 0.270 |
Why?
|
| Infection Control | 8 | 2021 | 983 | 0.270 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2021 | 669 | 0.270 |
Why?
|
| Sirolimus | 3 | 2012 | 1545 | 0.270 |
Why?
|
| Cryptococcosis | 2 | 2022 | 99 | 0.270 |
Why?
|
| Lymphoma | 2 | 2008 | 1897 | 0.260 |
Why?
|
| Aspergillus fumigatus | 2 | 2020 | 158 | 0.260 |
Why?
|
| Immunization Schedule | 5 | 2021 | 228 | 0.260 |
Why?
|
| Cytomegalovirus | 4 | 2020 | 751 | 0.260 |
Why?
|
| Emergency Service, Hospital | 2 | 2017 | 7875 | 0.260 |
Why?
|
| Immunity, Active | 2 | 2023 | 58 | 0.260 |
Why?
|
| Torsades de Pointes | 1 | 2007 | 78 | 0.260 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2021 | 3230 | 0.260 |
Why?
|
| Academic Medical Centers | 3 | 2014 | 2780 | 0.260 |
Why?
|
| Sensitivity and Specificity | 10 | 2023 | 14652 | 0.250 |
Why?
|
| Carrier State | 4 | 2021 | 529 | 0.250 |
Why?
|
| Enzyme-Linked Immunospot Assay | 4 | 2014 | 126 | 0.250 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2024 | 878 | 0.250 |
Why?
|
| HIV Envelope Protein gp120 | 4 | 2024 | 923 | 0.250 |
Why?
|
| Strongyloides stercoralis | 1 | 2005 | 23 | 0.240 |
Why?
|
| Strongyloidiasis | 1 | 2005 | 27 | 0.240 |
Why?
|
| Mass Vaccination | 3 | 2021 | 111 | 0.240 |
Why?
|
| Stem Cell Transplantation | 3 | 2008 | 1602 | 0.240 |
Why?
|
| South Africa | 6 | 2022 | 1867 | 0.240 |
Why?
|
| Antiparasitic Agents | 1 | 2005 | 41 | 0.240 |
Why?
|
| Ivermectin | 1 | 2005 | 48 | 0.240 |
Why?
|
| Virus Replication | 9 | 2022 | 2447 | 0.240 |
Why?
|
| Israel | 6 | 2021 | 725 | 0.240 |
Why?
|
| Healthcare Disparities | 6 | 2022 | 3413 | 0.240 |
Why?
|
| Alum Compounds | 1 | 2024 | 35 | 0.240 |
Why?
|
| Federal Government | 3 | 2021 | 265 | 0.230 |
Why?
|
| Drug Resistance, Viral | 4 | 2022 | 866 | 0.230 |
Why?
|
| Consumer Health Information | 3 | 2021 | 215 | 0.230 |
Why?
|
| Interleukin-2 | 1 | 2011 | 1896 | 0.230 |
Why?
|
| Antigens, Fungal | 3 | 2015 | 69 | 0.230 |
Why?
|
| Evolution, Molecular | 6 | 2022 | 1889 | 0.230 |
Why?
|
| Zygomycosis | 1 | 2004 | 7 | 0.230 |
Why?
|
| Alphapapillomavirus | 1 | 2007 | 219 | 0.230 |
Why?
|
| Digestive System | 2 | 2002 | 244 | 0.230 |
Why?
|
| Trichosporon | 1 | 2003 | 9 | 0.220 |
Why?
|
| Thrombosis | 4 | 2021 | 2949 | 0.220 |
Why?
|
| Seroepidemiologic Studies | 2 | 2022 | 404 | 0.220 |
Why?
|
| Hospitalization | 10 | 2022 | 10808 | 0.220 |
Why?
|
| Trust | 4 | 2021 | 533 | 0.220 |
Why?
|
| Myocarditis | 2 | 2021 | 802 | 0.220 |
Why?
|
| Attitude to Health | 3 | 2021 | 2020 | 0.220 |
Why?
|
| West Nile Fever | 1 | 2004 | 77 | 0.220 |
Why?
|
| Peptides, Cyclic | 2 | 2004 | 390 | 0.220 |
Why?
|
| Bone Marrow Transplantation | 3 | 2014 | 2729 | 0.220 |
Why?
|
| World Health Organization | 4 | 2022 | 1328 | 0.210 |
Why?
|
| Freezing | 2 | 2014 | 310 | 0.210 |
Why?
|
| Nasopharynx | 2 | 2024 | 419 | 0.210 |
Why?
|
| Paraproteinemias | 1 | 2006 | 252 | 0.210 |
Why?
|
| Echinococcosis, Pulmonary | 1 | 2003 | 7 | 0.210 |
Why?
|
| Organic Chemicals | 1 | 2024 | 211 | 0.210 |
Why?
|
| Minority Groups | 2 | 2021 | 1207 | 0.210 |
Why?
|
| Transplants | 1 | 2005 | 208 | 0.210 |
Why?
|
| Glioma | 1 | 2018 | 3493 | 0.210 |
Why?
|
| Echinococcosis, Hepatic | 1 | 2003 | 23 | 0.210 |
Why?
|
| False Positive Reactions | 4 | 2014 | 955 | 0.210 |
Why?
|
| Patient Selection | 5 | 2024 | 4255 | 0.200 |
Why?
|
| Drainage | 1 | 2008 | 1179 | 0.200 |
Why?
|
| Inflammation | 3 | 2021 | 10850 | 0.200 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2023 | 617 | 0.200 |
Why?
|
| Health Education | 7 | 2022 | 1060 | 0.200 |
Why?
|
| Toxoplasmosis | 1 | 2003 | 94 | 0.200 |
Why?
|
| Immunoassay | 3 | 2021 | 741 | 0.200 |
Why?
|
| Mycobacterium chelonae | 1 | 2022 | 12 | 0.200 |
Why?
|
| Single-Blind Method | 3 | 2021 | 1589 | 0.200 |
Why?
|
| Endocarditis | 2 | 2023 | 350 | 0.200 |
Why?
|
| Population Surveillance | 3 | 2021 | 2590 | 0.200 |
Why?
|
| Cord Blood Stem Cell Transplantation | 4 | 2014 | 316 | 0.200 |
Why?
|
| Endocarditis, Bacterial | 2 | 2023 | 434 | 0.200 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2014 | 755 | 0.190 |
Why?
|
| Body Fluids | 1 | 2024 | 321 | 0.190 |
Why?
|
| Cryptococcus neoformans | 1 | 2022 | 110 | 0.190 |
Why?
|
| Aluminum Hydroxide | 1 | 2022 | 55 | 0.190 |
Why?
|
| Hydroxylamines | 1 | 2021 | 39 | 0.190 |
Why?
|
| Measles | 2 | 2021 | 180 | 0.190 |
Why?
|
| Cytidine | 1 | 2021 | 59 | 0.190 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2020 | 1880 | 0.190 |
Why?
|
| Depsipeptides | 1 | 2002 | 95 | 0.190 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2022 | 68 | 0.190 |
Why?
|
| Dose-Response Relationship, Immunologic | 4 | 2020 | 355 | 0.190 |
Why?
|
| Gene Expression | 1 | 2014 | 7584 | 0.180 |
Why?
|
| RNA, Messenger | 7 | 2024 | 12768 | 0.180 |
Why?
|
| Lactams | 1 | 2022 | 159 | 0.180 |
Why?
|
| Leukocyte Reduction Procedures | 1 | 2020 | 13 | 0.180 |
Why?
|
| Salvage Therapy | 2 | 2007 | 1272 | 0.180 |
Why?
|
| Mandatory Programs | 1 | 2021 | 87 | 0.180 |
Why?
|
| Drug Industry | 3 | 2022 | 791 | 0.180 |
Why?
|
| Sputum | 1 | 2003 | 513 | 0.180 |
Why?
|
| Tobacco Industry | 1 | 2022 | 138 | 0.180 |
Why?
|
| Health Care Rationing | 2 | 2021 | 436 | 0.180 |
Why?
|
| Asymptomatic Diseases | 5 | 2021 | 586 | 0.180 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2012 | 3646 | 0.180 |
Why?
|
| T-Lymphocytes | 7 | 2024 | 10261 | 0.180 |
Why?
|
| Papillomavirus Vaccines | 1 | 2007 | 496 | 0.180 |
Why?
|
| Whooping Cough | 1 | 2021 | 87 | 0.180 |
Why?
|
| Biopsy | 3 | 2013 | 6763 | 0.180 |
Why?
|
| Enterococcus faecium | 1 | 2001 | 101 | 0.180 |
Why?
|
| Drug Resistance, Fungal | 3 | 2007 | 79 | 0.180 |
Why?
|
| Drug Therapy, Combination | 8 | 2022 | 6309 | 0.180 |
Why?
|
| Retrospective Studies | 24 | 2024 | 81514 | 0.170 |
Why?
|
| Leucine | 1 | 2022 | 546 | 0.170 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2022 | 150 | 0.170 |
Why?
|
| Social Isolation | 2 | 2021 | 366 | 0.170 |
Why?
|
| Fever of Unknown Origin | 2 | 2014 | 94 | 0.170 |
Why?
|
| Politics | 3 | 2021 | 822 | 0.170 |
Why?
|
| Antibodies, Bacterial | 3 | 2023 | 1476 | 0.170 |
Why?
|
| Staphylococcal Infections | 2 | 2008 | 1393 | 0.170 |
Why?
|
| Risk Factors | 19 | 2024 | 74840 | 0.170 |
Why?
|
| Proline | 1 | 2022 | 453 | 0.170 |
Why?
|
| Mucormycosis | 2 | 2011 | 104 | 0.170 |
Why?
|
| Epoprostenol | 1 | 2021 | 246 | 0.170 |
Why?
|
| Immunoglobulin M | 2 | 2023 | 1528 | 0.170 |
Why?
|
| Viremia | 2 | 2020 | 727 | 0.170 |
Why?
|
| Adenoviridae Infections | 2 | 2011 | 97 | 0.170 |
Why?
|
| Cytomegalovirus Vaccines | 1 | 2020 | 20 | 0.170 |
Why?
|
| Limbic Encephalitis | 2 | 2012 | 36 | 0.170 |
Why?
|
| Incidence | 9 | 2022 | 21480 | 0.170 |
Why?
|
| Dengue | 1 | 2003 | 257 | 0.170 |
Why?
|
| Heart Injuries | 1 | 2021 | 206 | 0.170 |
Why?
|
| Anthracyclines | 2 | 2015 | 284 | 0.170 |
Why?
|
| Chloroquine | 1 | 2021 | 276 | 0.160 |
Why?
|
| Proteoglycans | 5 | 2012 | 793 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 7 | 2021 | 7425 | 0.160 |
Why?
|
| Sisomicin | 1 | 2019 | 5 | 0.160 |
Why?
|
| Oxygen | 2 | 2021 | 4241 | 0.160 |
Why?
|
| Vaccines, Subunit | 2 | 2018 | 158 | 0.160 |
Why?
|
| Virus Activation | 4 | 2014 | 323 | 0.160 |
Why?
|
| Mandatory Reporting | 1 | 2020 | 123 | 0.160 |
Why?
|
| Azetidines | 1 | 2020 | 150 | 0.160 |
Why?
|
| Herpesvirus 6, Human | 2 | 2012 | 97 | 0.160 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2020 | 187 | 0.160 |
Why?
|
| Pyrazoles | 2 | 2020 | 2033 | 0.160 |
Why?
|
| Disaster Planning | 5 | 2024 | 559 | 0.160 |
Why?
|
| Dermatologic Agents | 1 | 2003 | 315 | 0.160 |
Why?
|
| Injections, Intravenous | 4 | 2017 | 1377 | 0.160 |
Why?
|
| HIV | 3 | 2014 | 1585 | 0.160 |
Why?
|
| Health Communication | 1 | 2022 | 216 | 0.160 |
Why?
|
| Transplantation Conditioning | 2 | 2018 | 1635 | 0.160 |
Why?
|
| Substance Abuse Detection | 1 | 2001 | 301 | 0.160 |
Why?
|
| HIV Envelope Protein gp41 | 2 | 2024 | 306 | 0.160 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2020 | 166 | 0.160 |
Why?
|
| Immunotherapy | 2 | 2020 | 4752 | 0.150 |
Why?
|
| Mutation | 9 | 2024 | 30198 | 0.150 |
Why?
|
| Bacteriophages | 1 | 2022 | 381 | 0.150 |
Why?
|
| Galectin 3 | 1 | 2020 | 238 | 0.150 |
Why?
|
| Private Sector | 1 | 2021 | 396 | 0.150 |
Why?
|
| Drug Discovery | 3 | 2021 | 1064 | 0.150 |
Why?
|
| Health Planning | 1 | 2020 | 233 | 0.150 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2008 | 1646 | 0.150 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 3 | 2019 | 213 | 0.150 |
Why?
|
| Immune Evasion | 1 | 2022 | 377 | 0.150 |
Why?
|
| Vulnerable Populations | 2 | 2020 | 718 | 0.150 |
Why?
|
| Immunoglobulin A | 4 | 2023 | 995 | 0.150 |
Why?
|
| Wounds and Injuries | 1 | 2011 | 2511 | 0.150 |
Why?
|
| Injections, Subcutaneous | 4 | 2021 | 682 | 0.150 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2016 | 304 | 0.150 |
Why?
|
| Public Policy | 1 | 2022 | 551 | 0.140 |
Why?
|
| Virulence | 4 | 2022 | 1289 | 0.140 |
Why?
|
| Immunity | 5 | 2022 | 1002 | 0.140 |
Why?
|
| Liver | 3 | 2009 | 7562 | 0.140 |
Why?
|
| Carbamates | 1 | 2019 | 191 | 0.140 |
Why?
|
| Immunity, Herd | 3 | 2022 | 48 | 0.140 |
Why?
|
| Government Regulation | 3 | 2022 | 525 | 0.140 |
Why?
|
| Purines | 1 | 2020 | 615 | 0.140 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 248 | 0.140 |
Why?
|
| Comorbidity | 4 | 2021 | 10563 | 0.140 |
Why?
|
| Risk | 8 | 2022 | 9591 | 0.140 |
Why?
|
| Health Resources | 2 | 2021 | 949 | 0.140 |
Why?
|
| Research Support as Topic | 1 | 2021 | 696 | 0.140 |
Why?
|
| Gastrointestinal Diseases | 2 | 2006 | 1203 | 0.140 |
Why?
|
| Immunologic Memory | 2 | 2021 | 1375 | 0.140 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 9071 | 0.140 |
Why?
|
| Cross Reactions | 5 | 2022 | 824 | 0.140 |
Why?
|
| Epitopes | 5 | 2024 | 2523 | 0.130 |
Why?
|
| Vaccines, Inactivated | 3 | 2021 | 185 | 0.130 |
Why?
|
| Choice Behavior | 1 | 2022 | 844 | 0.130 |
Why?
|
| Nitriles | 1 | 2022 | 982 | 0.130 |
Why?
|
| Rectum | 1 | 2021 | 896 | 0.130 |
Why?
|
| Latent Tuberculosis | 1 | 2019 | 223 | 0.130 |
Why?
|
| Drug Evaluation | 4 | 2020 | 641 | 0.130 |
Why?
|
| Acute Lung Injury | 1 | 2020 | 377 | 0.130 |
Why?
|
| Thrombocytopenia | 5 | 2021 | 1171 | 0.130 |
Why?
|
| Methicillin Resistance | 2 | 2008 | 198 | 0.130 |
Why?
|
| Research Personnel | 1 | 2021 | 590 | 0.130 |
Why?
|
| Waldenstrom Macroglobulinemia | 2 | 2018 | 1076 | 0.130 |
Why?
|
| Child | 22 | 2023 | 80564 | 0.130 |
Why?
|
| Pregnancy | 8 | 2021 | 30260 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2010 | 691 | 0.130 |
Why?
|
| Africa, Eastern | 1 | 2016 | 76 | 0.130 |
Why?
|
| Disk Diffusion Antimicrobial Tests | 1 | 2015 | 10 | 0.130 |
Why?
|
| Internship and Residency | 3 | 2021 | 5946 | 0.130 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2019 | 1917 | 0.130 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2015 | 18 | 0.130 |
Why?
|
| Cohort Studies | 17 | 2022 | 41649 | 0.130 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2016 | 98 | 0.130 |
Why?
|
| Colon | 2 | 2014 | 1795 | 0.130 |
Why?
|
| Nursing Homes | 2 | 2021 | 1084 | 0.130 |
Why?
|
| Neutralization Tests | 6 | 2022 | 735 | 0.130 |
Why?
|
| Vagina | 1 | 2021 | 848 | 0.130 |
Why?
|
| Recombinant Proteins | 3 | 2013 | 6493 | 0.130 |
Why?
|
| Fowlpox virus | 2 | 2012 | 21 | 0.120 |
Why?
|
| Echinocandins | 3 | 2012 | 57 | 0.120 |
Why?
|
| RNA, Viral | 5 | 2022 | 2864 | 0.120 |
Why?
|
| Lipopeptides | 3 | 2012 | 72 | 0.120 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2016 | 169 | 0.120 |
Why?
|
| Cardiology | 2 | 2023 | 1702 | 0.120 |
Why?
|
| Candidemia | 1 | 2015 | 46 | 0.120 |
Why?
|
| Health Policy | 3 | 2022 | 2698 | 0.120 |
Why?
|
| Acute Disease | 4 | 2012 | 7232 | 0.120 |
Why?
|
| Diagnosis, Differential | 7 | 2020 | 12976 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2007 | 1640 | 0.120 |
Why?
|
| Age Factors | 9 | 2024 | 18380 | 0.120 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 734 | 0.120 |
Why?
|
| Prospective Studies | 11 | 2025 | 54802 | 0.120 |
Why?
|
| Commerce | 1 | 2020 | 611 | 0.120 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2008 | 1069 | 0.120 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2007 | 2047 | 0.120 |
Why?
|
| Public Health Administration | 3 | 2022 | 241 | 0.120 |
Why?
|
| DNA, Fungal | 2 | 2013 | 276 | 0.120 |
Why?
|
| Publishing | 1 | 2022 | 835 | 0.120 |
Why?
|
| Turtles | 1 | 2014 | 40 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 11868 | 0.120 |
Why?
|
| Human Immunodeficiency Virus Proteins | 2 | 2011 | 56 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2009 | 4270 | 0.110 |
Why?
|
| Heart Failure | 1 | 2018 | 11840 | 0.110 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2014 | 82 | 0.110 |
Why?
|
| Kidney | 1 | 2009 | 7066 | 0.110 |
Why?
|
| Vascular Diseases | 1 | 2022 | 1159 | 0.110 |
Why?
|
| Galactose | 5 | 2014 | 299 | 0.110 |
Why?
|
| Hepatitis B Antibodies | 1 | 2014 | 156 | 0.110 |
Why?
|
| Plasmids | 4 | 2012 | 2274 | 0.110 |
Why?
|
| Interferon-gamma | 8 | 2024 | 3160 | 0.110 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2014 | 100 | 0.110 |
Why?
|
| Colitis | 2 | 2013 | 1239 | 0.110 |
Why?
|
| Mycophenolic Acid | 2 | 2014 | 346 | 0.110 |
Why?
|
| Travel | 2 | 2014 | 806 | 0.110 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2011 | 2587 | 0.110 |
Why?
|
| Bradyrhizobium | 1 | 2013 | 16 | 0.110 |
Why?
|
| Lentivirus | 1 | 2016 | 518 | 0.110 |
Why?
|
| Vaccines, Virus-Like Particle | 1 | 2014 | 44 | 0.110 |
Why?
|
| Aged, 80 and over | 13 | 2023 | 59489 | 0.110 |
Why?
|
| Hepatitis B Vaccines | 1 | 2014 | 178 | 0.110 |
Why?
|
| Oxygen Inhalation Therapy | 3 | 2021 | 418 | 0.110 |
Why?
|
| Lectins, C-Type | 1 | 2016 | 592 | 0.110 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 2 | 2024 | 117 | 0.110 |
Why?
|
| Administration, Oral | 4 | 2023 | 4015 | 0.100 |
Why?
|
| Virus Shedding | 3 | 2020 | 111 | 0.100 |
Why?
|
| Drug Combinations | 3 | 2022 | 2077 | 0.100 |
Why?
|
| Faculty, Medical | 1 | 2021 | 1219 | 0.100 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 2120 | 0.100 |
Why?
|
| Follow-Up Studies | 9 | 2021 | 39193 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2024 | 2339 | 0.100 |
Why?
|
| Nucleocapsid | 2 | 2023 | 60 | 0.100 |
Why?
|
| Genetic Variation | 4 | 2021 | 6610 | 0.100 |
Why?
|
| Research Design | 6 | 2022 | 6209 | 0.100 |
Why?
|
| Delphi Technique | 3 | 2021 | 893 | 0.100 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 1240 | 0.100 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2012 | 25 | 0.100 |
Why?
|
| Microbiological Techniques | 1 | 2013 | 96 | 0.100 |
Why?
|
| DNA | 4 | 2021 | 7202 | 0.100 |
Why?
|
| Advisory Committees | 3 | 2021 | 796 | 0.100 |
Why?
|
| Tissue Transplantation | 1 | 2012 | 128 | 0.100 |
Why?
|
| Virology | 1 | 2012 | 77 | 0.100 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2021 | 2187 | 0.100 |
Why?
|
| Lung | 4 | 2022 | 10033 | 0.100 |
Why?
|
| Diarrhea | 3 | 2018 | 1316 | 0.100 |
Why?
|
| Candidiasis, Invasive | 1 | 2012 | 27 | 0.100 |
Why?
|
| Liposomes | 3 | 2024 | 788 | 0.100 |
Why?
|
| Feces | 3 | 2005 | 1504 | 0.100 |
Why?
|
| Infusions, Intravenous | 3 | 2021 | 2229 | 0.100 |
Why?
|
| Paramyxoviridae Infections | 1 | 2012 | 57 | 0.100 |
Why?
|
| Respiration, Artificial | 2 | 2020 | 2709 | 0.100 |
Why?
|
| Roseolovirus Infections | 1 | 2012 | 50 | 0.100 |
Why?
|
| Polyomavirus Infections | 1 | 2014 | 194 | 0.090 |
Why?
|
| Risk Assessment | 9 | 2021 | 24282 | 0.090 |
Why?
|
| Plasma | 3 | 2020 | 579 | 0.090 |
Why?
|
| Drug Compounding | 1 | 2012 | 235 | 0.090 |
Why?
|
| Leadership | 1 | 2021 | 1392 | 0.090 |
Why?
|
| Mycology | 1 | 2011 | 13 | 0.090 |
Why?
|
| Th1 Cells | 1 | 2016 | 1039 | 0.090 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 2033 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2012 | 3737 | 0.090 |
Why?
|
| Graft Rejection | 4 | 2019 | 4499 | 0.090 |
Why?
|
| Mucorales | 1 | 2011 | 35 | 0.090 |
Why?
|
| Fatal Outcome | 2 | 2020 | 1831 | 0.090 |
Why?
|
| Herpesviridae Infections | 1 | 2012 | 268 | 0.090 |
Why?
|
| Metabolome | 1 | 2018 | 1005 | 0.090 |
Why?
|
| Tumor Virus Infections | 1 | 2014 | 440 | 0.090 |
Why?
|
| Interleukin-15 | 1 | 2012 | 186 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2007 | 1801 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2020 | 1984 | 0.090 |
Why?
|
| Endemic Diseases | 2 | 2022 | 189 | 0.090 |
Why?
|
| Mycobacterium | 1 | 2012 | 253 | 0.090 |
Why?
|
| Pharmacies | 1 | 2012 | 171 | 0.090 |
Why?
|
| Cold Temperature | 1 | 2014 | 794 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 6832 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 2329 | 0.090 |
Why?
|
| Dendritic Cells | 2 | 2024 | 2747 | 0.090 |
Why?
|
| Immunization | 3 | 2011 | 1219 | 0.090 |
Why?
|
| Lymphocyte Depletion | 1 | 2012 | 605 | 0.090 |
Why?
|
| Disease Reservoirs | 2 | 2021 | 124 | 0.090 |
Why?
|
| Receptors, Immunologic | 1 | 2016 | 1415 | 0.090 |
Why?
|
| Blood Proteins | 1 | 2015 | 1188 | 0.090 |
Why?
|
| Hypertension, Pulmonary | 1 | 2021 | 1604 | 0.090 |
Why?
|
| Europe | 3 | 2022 | 3423 | 0.080 |
Why?
|
| Antigens, CD34 | 1 | 2012 | 656 | 0.080 |
Why?
|
| Survival Rate | 4 | 2019 | 12795 | 0.080 |
Why?
|
| Pneumonia, Bacterial | 1 | 2012 | 318 | 0.080 |
Why?
|
| Recurrence | 4 | 2022 | 8501 | 0.080 |
Why?
|
| Animals | 17 | 2024 | 168764 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 4 | 2014 | 1701 | 0.080 |
Why?
|
| Reference Standards | 1 | 2013 | 1013 | 0.080 |
Why?
|
| Africa | 2 | 2022 | 725 | 0.080 |
Why?
|
| Liver Function Tests | 2 | 2009 | 525 | 0.080 |
Why?
|
| Developing Countries | 1 | 2022 | 2911 | 0.080 |
Why?
|
| Ganciclovir | 2 | 2008 | 257 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2019 | 4642 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2019 | 8733 | 0.080 |
Why?
|
| Forecasting | 3 | 2023 | 2936 | 0.080 |
Why?
|
| Sequence Analysis, RNA | 3 | 2021 | 2034 | 0.080 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2015 | 825 | 0.080 |
Why?
|
| Treatment Failure | 3 | 2020 | 2652 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2014 | 1187 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2021 | 2418 | 0.080 |
Why?
|
| Brain | 1 | 2016 | 27171 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2023 | 2921 | 0.080 |
Why?
|
| Metabolomics | 1 | 2018 | 1668 | 0.080 |
Why?
|
| Smoking | 2 | 2022 | 9081 | 0.080 |
Why?
|
| Histoplasmosis | 1 | 2008 | 63 | 0.070 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2014 | 790 | 0.070 |
Why?
|
| Siblings | 1 | 2012 | 828 | 0.070 |
Why?
|
| Cytokines | 4 | 2021 | 7421 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 21056 | 0.070 |
Why?
|
| Blood Platelets | 1 | 2018 | 2464 | 0.070 |
Why?
|
| Chemoprevention | 2 | 2020 | 327 | 0.070 |
Why?
|
| Viral Envelope Proteins | 1 | 2011 | 640 | 0.070 |
Why?
|
| Antibody Specificity | 1 | 2010 | 1061 | 0.070 |
Why?
|
| Trigeminal Nerve Diseases | 1 | 2008 | 47 | 0.070 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2014 | 838 | 0.070 |
Why?
|
| Piperidines | 3 | 2021 | 1664 | 0.070 |
Why?
|
| Prisoners | 2 | 2021 | 316 | 0.070 |
Why?
|
| Oral Ulcer | 1 | 2008 | 94 | 0.070 |
Why?
|
| Neutrophils | 1 | 2020 | 3776 | 0.070 |
Why?
|
| Community-Acquired Infections | 2 | 2008 | 470 | 0.070 |
Why?
|
| Fetal Blood | 2 | 2013 | 1369 | 0.070 |
Why?
|
| Consensus | 3 | 2023 | 3202 | 0.070 |
Why?
|
| DNA, Ribosomal | 2 | 2011 | 300 | 0.070 |
Why?
|
| Confusion | 1 | 2009 | 277 | 0.070 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 1789 | 0.070 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 14751 | 0.070 |
Why?
|
| Immunoglobulin Variable Region | 2 | 2021 | 419 | 0.070 |
Why?
|
| Ribavirin | 1 | 2009 | 395 | 0.070 |
Why?
|
| Candida | 2 | 2022 | 172 | 0.070 |
Why?
|
| Brazil | 2 | 2021 | 1248 | 0.070 |
Why?
|
| Liver Diseases | 3 | 2014 | 1303 | 0.070 |
Why?
|
| Trigeminal Ganglion | 1 | 2008 | 189 | 0.070 |
Why?
|
| Cryoelectron Microscopy | 2 | 2022 | 645 | 0.070 |
Why?
|
| Aminoglycosides | 1 | 2008 | 161 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 4353 | 0.070 |
Why?
|
| Drug Synergism | 2 | 2012 | 1749 | 0.070 |
Why?
|
| Multiple Myeloma | 2 | 2018 | 5197 | 0.070 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 399 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 3537 | 0.070 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2007 | 65 | 0.070 |
Why?
|
| Antigen-Antibody Complex | 2 | 2021 | 508 | 0.070 |
Why?
|
| Crystallography, X-Ray | 2 | 2022 | 1947 | 0.070 |
Why?
|
| Opioid-Related Disorders | 1 | 2001 | 2178 | 0.070 |
Why?
|
| Face | 1 | 2012 | 1028 | 0.070 |
Why?
|
| Postoperative Care | 1 | 2013 | 1470 | 0.070 |
Why?
|
| Interleukin-6 | 3 | 2021 | 3222 | 0.070 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2009 | 253 | 0.070 |
Why?
|
| Immunity, Innate | 3 | 2025 | 3081 | 0.070 |
Why?
|
| Occupational Exposure | 1 | 2016 | 1805 | 0.070 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 1394 | 0.070 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2007 | 272 | 0.060 |
Why?
|
| DNA Primers | 3 | 2011 | 2825 | 0.060 |
Why?
|
| Genotype | 3 | 2021 | 13024 | 0.060 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2006 | 142 | 0.060 |
Why?
|
| Databases, Factual | 4 | 2022 | 8067 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 2203 | 0.060 |
Why?
|
| Selection Bias | 1 | 2007 | 361 | 0.060 |
Why?
|
| Daptomycin | 1 | 2006 | 71 | 0.060 |
Why?
|
| Renal Insufficiency | 2 | 2009 | 804 | 0.060 |
Why?
|
| Mouth Diseases | 1 | 2008 | 240 | 0.060 |
Why?
|
| Veterinary Medicine | 1 | 2005 | 21 | 0.060 |
Why?
|
| History, 21st Century | 2 | 2022 | 1574 | 0.060 |
Why?
|
| Postoperative Complications | 4 | 2012 | 15747 | 0.060 |
Why?
|
| Necrosis | 1 | 2009 | 1617 | 0.060 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2006 | 238 | 0.060 |
Why?
|
| Cough | 2 | 2014 | 597 | 0.060 |
Why?
|
| Interferon-alpha | 1 | 2009 | 910 | 0.060 |
Why?
|
| Squalene | 1 | 2024 | 36 | 0.060 |
Why?
|
| Mass Screening | 1 | 2020 | 5446 | 0.060 |
Why?
|
| Polysorbates | 1 | 2024 | 46 | 0.060 |
Why?
|
| Cell Line | 2 | 2022 | 15543 | 0.060 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2006 | 266 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2009 | 1628 | 0.060 |
Why?
|
| Aerosols | 1 | 2007 | 633 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 5389 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 1275 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2007 | 552 | 0.060 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 1811 | 0.060 |
Why?
|
| Incidental Findings | 1 | 2009 | 697 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 1 | 2015 | 2895 | 0.060 |
Why?
|
| Metaphor | 1 | 2004 | 40 | 0.050 |
Why?
|
| Cyclophosphamide | 2 | 2023 | 2228 | 0.050 |
Why?
|
| Unnecessary Procedures | 1 | 2007 | 416 | 0.050 |
Why?
|
| Protein C | 1 | 2004 | 134 | 0.050 |
Why?
|
| Polyethylene Glycols | 1 | 2009 | 1188 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 2 | 2023 | 1078 | 0.050 |
Why?
|
| Base Sequence | 3 | 2022 | 12403 | 0.050 |
Why?
|
| Echinococcus | 1 | 2003 | 14 | 0.050 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 2003 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2007 | 614 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 8529 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2014 | 3046 | 0.050 |
Why?
|
| Sri Lanka | 1 | 2003 | 93 | 0.050 |
Why?
|
| Antibodies, Helminth | 1 | 2003 | 59 | 0.050 |
Why?
|
| Occupational Health | 2 | 2021 | 813 | 0.050 |
Why?
|
| Case-Control Studies | 4 | 2022 | 22223 | 0.050 |
Why?
|
| Virus Physiological Phenomena | 1 | 2022 | 15 | 0.050 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2007 | 592 | 0.050 |
Why?
|
| Monkeypox virus | 1 | 2022 | 43 | 0.050 |
Why?
|
| Macaca mulatta | 3 | 2018 | 2341 | 0.050 |
Why?
|
| 4-Quinolones | 1 | 2001 | 25 | 0.050 |
Why?
|
| Aging | 2 | 2016 | 8731 | 0.050 |
Why?
|
| HIV Seropositivity | 2 | 2019 | 961 | 0.050 |
Why?
|
| Asthma | 1 | 2021 | 6270 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2014 | 2226 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 8611 | 0.050 |
Why?
|
| Duodenum | 1 | 2005 | 495 | 0.050 |
Why?
|
| Webcasts as Topic | 1 | 2022 | 21 | 0.050 |
Why?
|
| Rubella Vaccine | 1 | 2021 | 23 | 0.050 |
Why?
|
| Qatar | 1 | 2021 | 40 | 0.050 |
Why?
|
| Clarithromycin | 1 | 2022 | 87 | 0.050 |
Why?
|
| Chickens | 1 | 2004 | 842 | 0.050 |
Why?
|
| Osteomyelitis | 1 | 2006 | 408 | 0.050 |
Why?
|
| Mumps Vaccine | 1 | 2021 | 15 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 12509 | 0.050 |
Why?
|
| Myeloablative Agonists | 2 | 2014 | 215 | 0.050 |
Why?
|
| Drug Interactions | 2 | 2022 | 1417 | 0.050 |
Why?
|
| Government | 1 | 2022 | 161 | 0.050 |
Why?
|
| Bahamas | 1 | 2021 | 9 | 0.050 |
Why?
|
| Child, Preschool | 7 | 2022 | 42500 | 0.050 |
Why?
|
| Americas | 1 | 2021 | 109 | 0.050 |
Why?
|
| Anticoagulants | 3 | 2021 | 4862 | 0.050 |
Why?
|
| Virginia | 1 | 2021 | 115 | 0.050 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2021 | 340 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 20124 | 0.040 |
Why?
|
| Platelet Factor 4 | 1 | 2021 | 132 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2022 | 507 | 0.040 |
Why?
|
| Consumer Product Safety | 1 | 2021 | 121 | 0.040 |
Why?
|
| Ireland | 1 | 2021 | 170 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 2004 | 696 | 0.040 |
Why?
|
| Hong Kong | 1 | 2021 | 169 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2023 | 639 | 0.040 |
Why?
|
| Civil Rights | 1 | 2021 | 129 | 0.040 |
Why?
|
| Azabicyclo Compounds | 1 | 2021 | 66 | 0.040 |
Why?
|
| Creatinine | 2 | 2022 | 1915 | 0.040 |
Why?
|
| Neuroendocrine Tumors | 1 | 2007 | 654 | 0.040 |
Why?
|
| Serology | 1 | 2020 | 7 | 0.040 |
Why?
|
| Chemokines | 1 | 2025 | 956 | 0.040 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2023 | 416 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2008 | 1376 | 0.040 |
Why?
|
| Kinetics | 2 | 2022 | 6274 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2008 | 1181 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 416 | 0.040 |
Why?
|
| Ships | 1 | 2020 | 53 | 0.040 |
Why?
|
| Injections, Intradermal | 2 | 2010 | 116 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2008 | 1187 | 0.040 |
Why?
|
| Bioethical Issues | 1 | 2021 | 119 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 2268 | 0.040 |
Why?
|
| Phylogeny | 2 | 2021 | 2832 | 0.040 |
Why?
|
| Compassionate Use Trials | 1 | 2020 | 49 | 0.040 |
Why?
|
| Iceland | 1 | 2020 | 183 | 0.040 |
Why?
|
| History, 18th Century | 1 | 2020 | 206 | 0.040 |
Why?
|
| Age of Onset | 2 | 2021 | 3344 | 0.040 |
Why?
|
| Allergy and Immunology | 1 | 2001 | 169 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2023 | 791 | 0.040 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 136 | 0.040 |
Why?
|
| Protein Structure, Quaternary | 1 | 2021 | 423 | 0.040 |
Why?
|
| Enteritis | 1 | 2001 | 163 | 0.040 |
Why?
|
| Interinstitutional Relations | 1 | 2021 | 234 | 0.040 |
Why?
|
| Herpesviridae | 2 | 2012 | 104 | 0.040 |
Why?
|
| Clostridium perfringens | 1 | 1999 | 29 | 0.040 |
Why?
|
| Syndrome | 2 | 2008 | 3271 | 0.040 |
Why?
|
| Coxiella burnetii | 1 | 2000 | 37 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2022 | 664 | 0.040 |
Why?
|
| Physicians, Family | 1 | 2001 | 349 | 0.040 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2020 | 123 | 0.040 |
Why?
|
| Q Fever | 1 | 2000 | 38 | 0.040 |
Why?
|
| Electrocardiography | 2 | 1983 | 6404 | 0.040 |
Why?
|
| Urinalysis | 1 | 2001 | 368 | 0.040 |
Why?
|
| Germany | 1 | 2022 | 882 | 0.040 |
Why?
|
| Culture Media | 1 | 2001 | 890 | 0.040 |
Why?
|
| Washington | 1 | 2020 | 314 | 0.040 |
Why?
|
| Nails, Malformed | 1 | 1999 | 34 | 0.040 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2021 | 939 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2002 | 833 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2012 | 3446 | 0.040 |
Why?
|
| Hospitals, Veterans | 1 | 2001 | 395 | 0.040 |
Why?
|
| Boston | 5 | 2024 | 9338 | 0.040 |
Why?
|
| Health Status Disparities | 2 | 2021 | 1880 | 0.040 |
Why?
|
| Cyclonic Storms | 1 | 2021 | 121 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2006 | 1971 | 0.040 |
Why?
|
| Coronavirus | 1 | 2021 | 155 | 0.040 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 136 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 330 | 0.040 |
Why?
|
| Information Seeking Behavior | 1 | 2020 | 116 | 0.040 |
Why?
|
| Hepatitis C Antibodies | 1 | 2019 | 151 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2021 | 326 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2011 | 2283 | 0.040 |
Why?
|
| Peptides | 2 | 2015 | 4331 | 0.040 |
Why?
|
| Cholecystitis | 1 | 1999 | 181 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 201 | 0.040 |
Why?
|
| Tuberculin Test | 1 | 2019 | 205 | 0.040 |
Why?
|
| Troponin | 1 | 2022 | 533 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 10729 | 0.040 |
Why?
|
| Antitubercular Agents | 2 | 2019 | 1384 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 13451 | 0.040 |
Why?
|
| Medical Order Entry Systems | 1 | 2004 | 521 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 790 | 0.040 |
Why?
|
| Demography | 1 | 2023 | 1641 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 18071 | 0.040 |
Why?
|
| Delivery of Health Care | 3 | 2020 | 5370 | 0.040 |
Why?
|
| Religion | 1 | 2021 | 376 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2005 | 1797 | 0.040 |
Why?
|
| HIV Protease Inhibitors | 1 | 2020 | 430 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2021 | 751 | 0.040 |
Why?
|
| Oligosaccharides | 1 | 2020 | 406 | 0.040 |
Why?
|
| Ectodermal Dysplasia | 1 | 1999 | 106 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 1731 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2021 | 852 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2021 | 657 | 0.040 |
Why?
|
| Infant, Newborn | 5 | 2024 | 26346 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 382 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2023 | 1441 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2020 | 335 | 0.040 |
Why?
|
| Equipment and Supplies | 1 | 2020 | 273 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2006 | 1424 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2021 | 670 | 0.040 |
Why?
|
| Muscular Diseases | 1 | 2022 | 550 | 0.040 |
Why?
|
| Rubella | 1 | 2018 | 55 | 0.040 |
Why?
|
| ABO Blood-Group System | 1 | 2020 | 380 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2021 | 1228 | 0.040 |
Why?
|
| Education, Distance | 1 | 2021 | 262 | 0.040 |
Why?
|
| New York City | 1 | 2020 | 733 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2020 | 354 | 0.040 |
Why?
|
| Keratins | 1 | 1999 | 498 | 0.040 |
Why?
|
| Sweden | 1 | 2020 | 1381 | 0.040 |
Why?
|
| Cysts | 1 | 2003 | 684 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 17594 | 0.040 |
Why?
|
| Spleen | 1 | 2003 | 2296 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2001 | 629 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2008 | 2074 | 0.030 |
Why?
|
| Mumps | 1 | 2018 | 70 | 0.030 |
Why?
|
| Public Opinion | 1 | 2021 | 482 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2025 | 9525 | 0.030 |
Why?
|
| Tongue | 1 | 2020 | 405 | 0.030 |
Why?
|
| Financing, Government | 1 | 2020 | 473 | 0.030 |
Why?
|
| Lipids | 2 | 2024 | 3315 | 0.030 |
Why?
|
| Troponin T | 1 | 2021 | 785 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2020 | 547 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2018 | 415 | 0.030 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2021 | 365 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 4348 | 0.030 |
Why?
|
| Hospital Administration | 1 | 2020 | 352 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2020 | 651 | 0.030 |
Why?
|
| Nose | 1 | 2020 | 519 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2021 | 1001 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2020 | 1617 | 0.030 |
Why?
|
| Haemophilus Vaccines | 1 | 1996 | 70 | 0.030 |
Why?
|
| Lung Diseases | 2 | 2004 | 1940 | 0.030 |
Why?
|
| Standard of Care | 1 | 2020 | 567 | 0.030 |
Why?
|
| Professional-Patient Relations | 1 | 2021 | 721 | 0.030 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2021 | 572 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 2001 | 830 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2021 | 959 | 0.030 |
Why?
|
| Platelet Count | 1 | 2018 | 782 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 2021 | 744 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2022 | 1737 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2012 | 10070 | 0.030 |
Why?
|
| Caspase 1 | 1 | 2016 | 227 | 0.030 |
Why?
|
| Safety Management | 1 | 2021 | 763 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2022 | 2721 | 0.030 |
Why?
|
| Tetanus Toxoid | 1 | 1996 | 188 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2022 | 5526 | 0.030 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 1996 | 112 | 0.030 |
Why?
|
| Japan | 1 | 2020 | 1415 | 0.030 |
Why?
|
| Child Behavior | 1 | 2021 | 865 | 0.030 |
Why?
|
| Graft Survival | 2 | 2019 | 3890 | 0.030 |
Why?
|
| Placebo Effect | 1 | 2019 | 514 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 1333 | 0.030 |
Why?
|
| Dizziness | 1 | 2018 | 269 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2022 | 1016 | 0.030 |
Why?
|
| China | 1 | 2021 | 2385 | 0.030 |
Why?
|
| Health | 2 | 2012 | 397 | 0.030 |
Why?
|
| Cyclohexenes | 1 | 2014 | 15 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2024 | 2573 | 0.030 |
Why?
|
| Phenotype | 2 | 2024 | 16721 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 9373 | 0.030 |
Why?
|
| Health Facilities | 1 | 2020 | 577 | 0.030 |
Why?
|
| Monoterpenes | 1 | 2014 | 21 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2020 | 2910 | 0.030 |
Why?
|
| Massachusetts | 2 | 2020 | 8875 | 0.030 |
Why?
|
| Self Care | 1 | 2020 | 800 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 2108 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 938 | 0.030 |
Why?
|
| Cardiomyopathies | 1 | 2007 | 2067 | 0.030 |
Why?
|
| Terpenes | 1 | 2014 | 102 | 0.030 |
Why?
|
| India | 1 | 2021 | 2334 | 0.030 |
Why?
|
| Piperacillin | 1 | 2014 | 37 | 0.030 |
Why?
|
| Back Pain | 1 | 2018 | 544 | 0.030 |
Why?
|
| Quinazolines | 1 | 2021 | 1364 | 0.030 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2014 | 61 | 0.030 |
Why?
|
| Penicillanic Acid | 1 | 2014 | 41 | 0.030 |
Why?
|
| Sweet Syndrome | 1 | 2014 | 59 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2024 | 22332 | 0.030 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2016 | 287 | 0.030 |
Why?
|
| Physicians, Primary Care | 1 | 2020 | 622 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2014 | 355 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 891 | 0.030 |
Why?
|
| Sesquiterpenes | 1 | 2014 | 175 | 0.030 |
Why?
|
| Enterovirus Infections | 1 | 1994 | 74 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2001 | 961 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 1061 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 1514 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2022 | 2446 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 953 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 20659 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2013 | 152 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2023 | 1510 | 0.030 |
Why?
|
| BK Virus | 1 | 2014 | 121 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2021 | 2761 | 0.030 |
Why?
|
| Prognosis | 4 | 2018 | 29922 | 0.030 |
Why?
|
| Glycosylation | 1 | 2016 | 1100 | 0.030 |
Why?
|
| Drug Contamination | 1 | 2014 | 152 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2003 | 12056 | 0.030 |
Why?
|
| Lymphatic Diseases | 1 | 2014 | 317 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2024 | 1964 | 0.030 |
Why?
|
| Clostridium Infections | 1 | 1999 | 564 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2015 | 648 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2021 | 2113 | 0.030 |
Why?
|
| Chest Pain | 1 | 1999 | 1100 | 0.030 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 689 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2013 | 301 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 2570 | 0.020 |
Why?
|
| Mycobacterium avium Complex | 1 | 2012 | 66 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2020 | 9347 | 0.020 |
Why?
|
| Electroporation | 1 | 2013 | 238 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 2015 | 536 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2021 | 1168 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2016 | 1638 | 0.020 |
Why?
|
| Algorithms | 3 | 2015 | 14071 | 0.020 |
Why?
|
| Patient Participation | 1 | 2021 | 1455 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2018 | 1069 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2022 | 5379 | 0.020 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 41 | 0.020 |
Why?
|
| Drug Dosage Calculations | 1 | 2012 | 116 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2021 | 2686 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2022 | 2692 | 0.020 |
Why?
|
| RNA, Ribosomal, 18S | 1 | 2011 | 54 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2001 | 2243 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 2 | 2013 | 4772 | 0.020 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 149 | 0.020 |
Why?
|
| Mice | 3 | 2024 | 81819 | 0.020 |
Why?
|
| Fatigue | 1 | 2018 | 1549 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2020 | 2631 | 0.020 |
Why?
|
| Cross Infection | 1 | 2020 | 1427 | 0.020 |
Why?
|
| Drug Design | 1 | 2015 | 1042 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 2334 | 0.020 |
Why?
|
| Skin Diseases | 1 | 1999 | 1088 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2021 | 2778 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2016 | 1520 | 0.020 |
Why?
|
| Disease Management | 1 | 2020 | 2535 | 0.020 |
Why?
|
| Education, Medical | 1 | 2001 | 1746 | 0.020 |
Why?
|
| Exanthema | 1 | 2014 | 502 | 0.020 |
Why?
|
| Protein Binding | 1 | 2022 | 9296 | 0.020 |
Why?
|
| Catheter-Related Infections | 1 | 2012 | 279 | 0.020 |
Why?
|
| Cephalosporins | 2 | 2001 | 200 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2012 | 6203 | 0.020 |
Why?
|
| Health Behavior | 1 | 2021 | 2650 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2020 | 5302 | 0.020 |
Why?
|
| Infant | 5 | 2021 | 36386 | 0.020 |
Why?
|
| Gene Products, gag | 1 | 2010 | 317 | 0.020 |
Why?
|
| Defective Viruses | 1 | 2009 | 88 | 0.020 |
Why?
|
| Viral Structural Proteins | 1 | 2009 | 93 | 0.020 |
Why?
|
| Myocardial Ischemia | 1 | 1999 | 2128 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2021 | 9649 | 0.020 |
Why?
|
| Decision Making | 1 | 2022 | 3965 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3850 | 0.020 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2014 | 518 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2020 | 3956 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2013 | 1477 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 2194 | 0.020 |
Why?
|
| Cell Movement | 1 | 2020 | 5194 | 0.020 |
Why?
|
| Tuberculosis | 1 | 2021 | 2012 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 1560 | 0.020 |
Why?
|
| Genome, Bacterial | 1 | 2013 | 797 | 0.020 |
Why?
|
| Periapical Abscess | 1 | 2008 | 17 | 0.020 |
Why?
|
| Parotitis | 1 | 2008 | 28 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2016 | 2485 | 0.020 |
Why?
|
| Candidiasis, Oral | 1 | 2008 | 57 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2015 | 13400 | 0.020 |
Why?
|
| ROC Curve | 1 | 2015 | 3620 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3800 | 0.020 |
Why?
|
| Amnesia, Anterograde | 1 | 2007 | 20 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2007 | 318 | 0.020 |
Why?
|
| Skin | 1 | 2021 | 4489 | 0.020 |
Why?
|
| Canarypox virus | 1 | 2007 | 10 | 0.020 |
Why?
|
| Nose Diseases | 1 | 2008 | 79 | 0.020 |
Why?
|
| Critical Care | 1 | 2020 | 2712 | 0.020 |
Why?
|
| Trigeminal Neuralgia | 1 | 2008 | 108 | 0.020 |
Why?
|
| Sex Factors | 1 | 2021 | 10603 | 0.020 |
Why?
|
| Diabetes Insipidus | 1 | 2007 | 143 | 0.020 |
Why?
|
| Disease Progression | 1 | 2024 | 13632 | 0.020 |
Why?
|
| Intestines | 1 | 2015 | 1906 | 0.020 |
Why?
|
| Chromium | 1 | 2007 | 132 | 0.020 |
Why?
|
| Prevalence | 1 | 2003 | 15842 | 0.020 |
Why?
|
| Sepsis | 1 | 1999 | 2606 | 0.020 |
Why?
|
| Cystic Fibrosis | 1 | 2014 | 1287 | 0.020 |
Why?
|
| Stomatitis | 1 | 2008 | 270 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2008 | 432 | 0.020 |
Why?
|
| Malaria Vaccines | 1 | 2006 | 165 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2010 | 962 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 15398 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1994 | 1660 | 0.010 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2007 | 391 | 0.010 |
Why?
|
| Medication Systems, Hospital | 1 | 2004 | 154 | 0.010 |
Why?
|
| Pneumococcal Infections | 1 | 2008 | 527 | 0.010 |
Why?
|
| Physicians | 1 | 2021 | 4588 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2010 | 5020 | 0.010 |
Why?
|
| Periodontitis | 1 | 2008 | 576 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 18293 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 1983 | 11499 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 12807 | 0.010 |
Why?
|
| Anemia | 1 | 2011 | 1511 | 0.010 |
Why?
|
| Retirement | 1 | 1983 | 198 | 0.010 |
Why?
|
| Ceftazidime | 1 | 2001 | 57 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 26318 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2013 | 2531 | 0.010 |
Why?
|
| Cause of Death | 1 | 2012 | 3708 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2008 | 1494 | 0.010 |
Why?
|
| Rickettsia rickettsii | 1 | 2000 | 5 | 0.010 |
Why?
|
| Ehrlichia | 1 | 2000 | 6 | 0.010 |
Why?
|
| Anuria | 1 | 1999 | 15 | 0.010 |
Why?
|
| Cefuroxime | 1 | 1999 | 23 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 3247 | 0.010 |
Why?
|
| Models, Biological | 1 | 2015 | 9443 | 0.010 |
Why?
|
| Amygdala | 1 | 2007 | 1377 | 0.010 |
Why?
|
| Interdisciplinary Communication | 1 | 2004 | 932 | 0.010 |
Why?
|
| Hemolysis | 1 | 1999 | 406 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 2001 | 601 | 0.010 |
Why?
|
| Emphysema | 1 | 1999 | 234 | 0.010 |
Why?
|
| American Heart Association | 1 | 2001 | 1047 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2001 | 1158 | 0.010 |
Why?
|
| Gambia | 1 | 1996 | 104 | 0.010 |
Why?
|
| Haemophilus Infections | 1 | 1996 | 93 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 1999 | 1210 | 0.010 |
Why?
|
| Medical Records | 1 | 2001 | 1409 | 0.010 |
Why?
|
| Hippocampus | 1 | 2007 | 3775 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 1999 | 1740 | 0.010 |
Why?
|
| Meningitis, Viral | 1 | 1994 | 49 | 0.010 |
Why?
|
| Point Mutation | 1 | 1999 | 1590 | 0.010 |
Why?
|
| Teaching | 1 | 2001 | 1169 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2004 | 2098 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2006 | 2495 | 0.010 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1996 | 587 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 2001 | 1135 | 0.010 |
Why?
|
| Paralysis | 1 | 1994 | 248 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2007 | 18973 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 2001 | 1662 | 0.010 |
Why?
|
| Pedigree | 1 | 1999 | 4526 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 10429 | 0.010 |
Why?
|
| Encephalitis | 1 | 1994 | 441 | 0.010 |
Why?
|
| Health Status | 1 | 1983 | 4080 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2001 | 3685 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1983 | 8532 | 0.000 |
Why?
|
| Regression Analysis | 1 | 1996 | 6322 | 0.000 |
Why?
|
| Pregnancy Outcome | 1 | 1996 | 2966 | 0.000 |
Why?
|
| Coronary Disease | 1 | 1999 | 5912 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 36532 | 0.000 |
Why?
|